SEC Form 4 · accession 0001178913-18-001607
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anna Kazanchyan
Director
Period of report
May 8, 2018
Accepted (ET)
May 10, 2018 · 5:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2,F1,F3 | May 8, 2018 | A | 14,829 | $0.00 | A | 27,760 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
- F2The ordinary shares underlying this restricted share unit award vest over a period of three years from May 8, 2018 (33.3% on each anniversary of such date) and ending May 8, 2021.
- F3The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 12,931 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security and ii) the 14,829 ordinary shares sub-ject to unvested restricted share units granted on May 8, 2018 and first reported on this Form 4.